Critical Warnings & Restrictions

Basic Xatral Information

• INN (International Nonproprietary Name): Alfuzosin.
• Brand Names Available In United Kingdom: Xatral; generics include Alfuzosin Teva, Alfuzosin Mylan, Alfuzosin Sandoz and other generic suppliers.
• ATC Code: G04CA01.
• Forms & Dosages: Extended/prolonged‑release tablets, commonly 10 mg once daily; some generics available as 5 mg or rarely 2.5 mg formulations.
• Manufacturers In United Kingdom: Originator company Sanofi; generics supplied by Teva, Sandoz, Mylan, Krka, Actavis, Torrent and others.
• Registration Status In United Kingdom: MHRA‑authorised for use in adult men with BPH.
• OTC / Rx Classification: Prescription‑only medicine (POM) in the UK.

High-Risk Groups

• Alfuzosin is authorised for adult men with benign prostatic hyperplasia only, and is not approved for women or children.
• Prescribers must not issue alfuzosin to patients with moderate or severe hepatic insufficiency because it is contraindicated in these conditions.
• Exercise caution in mild hepatic impairment and consult a specialist before use in severe renal impairment; mild to moderate renal impairment usually needs no initial dose change.
• Elderly patients may be more susceptible to postural hypotension and syncope, particularly those already taking antihypertensives or with a history of falls.
• Patients with a known hypersensitivity to alfuzosin or any excipient must not take the medicine.
• Before starting alfuzosin, clinicians should check current medicines for strong CYP3A4 inhibitors such as ketoconazole or ritonavir, which can raise alfuzosin levels and should be avoided.
• Ask about recent or planned eye surgery, especially cataract operations, because alfuzosin is associated with intraoperative floppy iris syndrome (IFIS); notify the ophthalmic surgeon if the patient is taking or has taken alfuzosin.

Prescriber Checklist Before Initiating Alfuzosin

• Confirm indication: symptomatic BPH in an adult man only.
• Check allergy history for alfuzosin or excipients.
• Assess liver function and avoid use in moderate/severe hepatic insufficiency.
• Review renal function; seek specialist input for severe renal impairment.
• Review concomitant medicines for strong CYP3A4 inhibitors (eg ketoconazole, ritonavir) and other antihypertensives or nitrates.
• Ask about recent or planned cataract surgery and record counselling about IFIS.
• Advise baseline blood pressure and arrange follow‑up monitoring after initiation.

Interaction With Activities

• Alfuzosin can cause dizziness, lightheadedness and rarely syncope due to orthostatic hypotension, particularly when standing or on initial dosing.
• Advise patients to rise slowly from sitting or lying positions to reduce risk of falls or fainting.
• Warn about driving or operating machinery until the individual knows how alfuzosin affects them; test reactions at home first.
• Advise limiting alcohol when starting alfuzosin or after dose changes because alcohol can increase dizziness and hypotensive effects.

Can I Drive After Taking It In The United Kingdom?

Short answer: Not until you know how the medicine affects you.

If you feel dizzy, lightheaded or faint, do not drive or operate heavy machinery.

This advice aligns with DVLA safety responsibilities and NHS guidance on medicines that impair alertness.

Usage Basics

INN And UK Brand/Generic Availability

INN

Alfuzosin.

Brand Names

Xatral (widely used in Europe); Uroxatral is the US trade name for the 10 mg extended‑release product.

ATC Code

G04CA01.

• Major manufacturers and suppliers: Sanofi (originator), Teva, Sandoz, Mylan, Krka, Actavis, Torrent and others supply Xatral and generic alfuzosin products across EU/UK markets.
• Generics such as Alfuzosin Teva, Alfuzosin Mylan and Alfuzosin Sandoz are available in the UK market via community pharmacies and NHS supply where locally approved.
• NHS prescribers should check local formulary status and commissioning arrangements when selecting a specific brand or generic supplier.

Legal Classification And Prescription Status

• Alfuzosin is a prescription‑only medicine (POM) in the United Kingdom and is MHRA‑authorised.
• Supply routes include NHS GP prescription, private prescription or NHS electronic prescription into community pharmacies and registered online pharmacy services.
• Alfuzosin is not available over the counter or as a pharmacy‑only medicine.

Dosing Guide

Standard Regimen And Administration

• The standard adult dose for BPH is 10 mg prolonged/extended‑release tablet once daily taken after the same meal each day to ensure consistent absorption and reduce hypotension risk.
• Alfuzosin is intended for chronic use to manage ongoing lower urinary tract symptoms due to BPH and should be reviewed periodically for efficacy and tolerability.
• Not approved for women or children, and not indicated outside the adult male BPH population.

Before Starting

• Confirm the patient is an adult male with symptomatic BPH.
• Discuss timing with meals and the importance of a consistent daily routine.
• Explain the risk of dizziness and advise on orthostatic precautions.
• Arrange baseline blood pressure measurement and medication reconciliation for CYP3A4 inhibitors.

Dose Adjustments For Comorbidities

• No routine dose reduction is required solely for age, but monitor older patients closely for hypotension and syncope.
• Mild to moderate renal impairment generally requires no initial dose adjustment; seek specialist advice for severe renal impairment and consider avoiding use.
• Contraindicated in moderate to severe hepatic impairment; use with caution in mild liver disease only when benefits outweigh risks.
• Avoid co‑administration with strong CYP3A4 inhibitors which can markedly increase exposure to alfuzosin.

What If I Miss A Dose?

Take the missed dose as soon as you remember unless it is almost time for the next scheduled dose.

Do not take a double dose to make up for a missed tablet.

If unsure, contact a pharmacist or GP for advice.

Interaction Chart

Food And Drinks

• Take alfuzosin after the same meal each day because food increases and stabilises absorption and can reduce the risk of hypotension.
• Alcohol can increase dizziness and blood pressure lowering and should be limited when starting alfuzosin or after dose changes.
• No clinically significant interactions are noted with tea or coffee, but advise on adequate hydration and orthostatic precautions.

Common Drug Interactions

Report suspected adverse drug reactions to the MHRA Yellow Card scheme as part of post‑marketing surveillance.

User Reports & Trends

What patients commonly say about alfuzosin on UK sources such as NHS patient leaflets and patient forums.

• Many users report improved urinary flow, reduced urinary hesitancy and fewer nocturnal visits within days to weeks of starting alfuzosin.
• Common side effects reported by patients include dizziness, transient fatigue and occasional gastrointestinal upset.
• Some patients note rapid symptomatic relief but emphasise that alfuzosin does not reduce prostate size—symptom control is the primary benefit.
• Timing with meals and interactions with blood pressure medicines are frequent real‑world adherence issues leading to missed doses or stopping therapy.
• IFIS concerns arise in posts from patients with prior cataract surgery; many advise telling the eye surgeon about current or past alfuzosin use.

Writers should validate forum findings against NHS guidance and MHRA safety alerts before publishing and quote authoritative sources for clinical claims.

Access & Purchase Options

High‑Street Chains And NHS Routes

• Community pharmacies dispensing alfuzosin include major chains such as Boots, LloydsPharmacy and Superdrug, as well as independent pharmacies.
• Prescriptions are supplied via NHS GP‑issued paper or electronic prescriptions, and NHS e‑prescribing (EPS) is widely used for repeat dispensing.
• MHRA‑authorised supply requires a valid prescription before a community pharmacy may dispense alfuzosin.

Online Pharmacies And Private Prescriptions

• Registered online pharmacies and private prescribers may supply alfuzosin on receipt of a valid prescription; ensure the service is GPhC‑registered and displays appropriate UK registration details.
• Be cautious of unregulated sellers that do not require a prescription or do not display registration details.

Checklist For Patients When Obtaining Alfuzosin

• Bring a current prescription or ensure an NHS electronic prescription is sent to your nominated pharmacy.
• Provide an up‑to‑date list of medicines including any antifungal or antiviral treatments (eg ketoconazole, ritonavir).
• Tell the pharmacist if you are on blood pressure medicines, nitrates or PDE5 inhibitors.
• Advise about any recent or planned cataract surgery and any allergy history.
• Carry proof of prescription exemption if applicable (eg age, war pension, low income) when collecting from a high‑street pharmacy.

Pharmacists have a duty to counsel patients, check interactions and offer NHS Medicines Use Reviews where available.

In our online pharmacy, xatral is supplied only with a valid prescription and can be delivered discreetly across the United Kingdom.

Mechanism & Pharmacology

Simplified Explanation For Patients

• Alfuzosin is an alpha‑1 adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck to ease urine flow.
• It relieves the symptoms of BPH but does not shrink the prostate gland itself.
• Patients can expect symptomatic relief over days to several weeks, and chronic treatment is common where benefits persist.

Clinical Pharmacology Terms

Alpha‑1 Adrenoceptor

A receptor on smooth muscle in the prostate and bladder neck that, when blocked, causes muscle relaxation and improvement in urinary flow.

Extended‑Release / Prolonged‑Release

Formulation that releases medicine slowly to produce steady plasma concentrations and reduce peak‑related side effects.

CYP3A4

Drug‑metabolising enzyme important in alfuzosin metabolism; inhibitors can raise alfuzosin levels and increase adverse effects.

A short diagram is useful on web pages showing the prostate and bladder neck where alfuzosin acts to relax muscle and improve urine flow.

Indications & Off‑Label Uses

MHRA‑Approved Indications

• Alfuzosin is approved for the symptomatic treatment of benign prostatic hyperplasia (BPH) in adult men at a dose of 10 mg once daily after the same meal.
• It is not indicated for women or children and is prescription‑only.

Off‑Label Practices And NHS Context

• Some clinicians may select alfuzosin as an alternative alpha‑blocker for lower urinary tract symptoms where tolerability differs, but off‑label choices should be clearly documented.
• Off‑label use should be justified in the clinical record, discussed with the patient and supported by evidence where available.

When Prescribers Might Choose Alfuzosin

• When a patient requires once‑daily treatment and prefers an extended‑release formulation.
• When prior alpha‑blocker therapy has been ineffective or poorly tolerated and the prescriber judges alfuzosin appropriate.
• When ejaculatory side effects of more uroselective agents are a concern and the overall risk–benefit supports alfuzosin use.

Off‑Label Documentation Checklist

• Record indication and rationale for choosing alfuzosin.
• Discuss risks including hypotension and IFIS with the patient and obtain verbal consent.
• Arrange follow‑up and monitoring plan in the clinical notes.

Key Clinical Findings

Summary of recent UK/EU evidence (2022–2025) on alfuzosin effectiveness and tolerability.

• Real‑world cohort studies and meta‑analyses report improvement in IPSS (International Prostate Symptom Score) and increases in peak urine flow (Qmax) compared with placebo.
• Symptomatic relief typically appears early, often within days, with full benefit over several weeks.
• Comparisons with other alpha blockers such as tamsulosin and silodosin show broadly similar efficacy but different side‑effect profiles.
• Alfuzosin is associated more with orthostatic hypotension and dizziness, while alpha‑1A selective agents (eg tamsulosin) are more commonly linked to ejaculatory dysfunction.
• Longitudinal studies emphasise the need to monitor older adults for falls and syncope when on alfuzosin.

Link to MHRA and NICE guidance when referencing prescribing and safety details for full appraisal.

Alternatives Matrix

NHS Prescribing Alternatives Table

Pros And Cons Checklist

• Pros Of Alfuzosin: once‑daily extended‑release dosing, effective symptom relief, fewer ejaculatory effects than some alpha‑1A agents.
• Cons Of Alfuzosin: risk of orthostatic hypotension and syncope, contraindicated in moderate/severe hepatic impairment, IFIS risk for cataract surgery.
• Choose individual therapy based on cardiovascular comorbidity, cataract surgery plans and patient preference.

Common Questions

• How long until I feel better? Many patients notice improvement within days, though full benefit can take several weeks.
• Can I stop other blood pressure meds? Never stop antihypertensive medication without GP review; alfuzosin can add to blood pressure lowering.
• What about cataract surgery? Tell your ophthalmic surgeon if you are taking or have taken alfuzosin because of IFIS risk; do not stop medication without clinical advice.
• Is it safe long term? Alfuzosin is used long term when effective and tolerated; arrange reviews including BP checks and review of liver/renal status where indicated.

Use an FAQ accordion on web pages for readability and signpost NHS and MHRA resources for more detailed guidance.

NHS Cost & Access Comparison

Generic suppliers such as Milpharm, Zentiva and Aurobindo help lower private costs and availability for patients seeking branded or generic alfuzosin tablets.

Registration & Regulation

MHRA Approval And Monitoring

• Alfuzosin is MHRA‑authorised in the UK and post‑marketing surveillance is maintained through Yellow Card reporting for suspected adverse reactions.
• Manufacturers include Sanofi as the originator and multiple generic suppliers who hold marketing authorisations depending on the product and presentation.

NHS Prescribing Framework

• Prescribe in line with NICE guidance for BPH and local formularies where applicable.
• Use the Electronic Prescription Service (EPS) for community dispensing where available and document assessment including IPSS, renal and liver status and concomitant medication review before initiation.

Prescriber Flowchart

• Assessment → Consent & Counselling → Initiation (10 mg once daily after same meal) → Review at 4–12 weeks → Ongoing annual review and BP monitoring.

Regulatory contraindications such as moderate/severe hepatic insufficiency and strong CYP3A4 interactions must be considered before prescribing.

Storage & Handling

Household Storage Advice

• Store alfuzosin at room temperature (20–25°C / 68–77°F) and protect from moisture and heat.
• Keep the medicine in its original blister pack until use.
• Avoid storing medicine in bathrooms where damp and heat are common; use a dry cupboard away from direct sunlight.

NHS And Pharmacist Guidance

• Pharmacists should check expiry dates, advise safe storage and inform patients about safe disposal options.
• Return unused or expired medicines to a pharmacy for NHS‑approved disposal; do not flush or throw into household waste.

Patient Checklist

• Keep in original pack and out of reach of children.
• Avoid bathroom storage; choose a dry, cool cupboard.
• Carry in original packaging with prescription when travelling.

Guidelines For Proper Use

UK Pharmacist Counselling Style

• Explain the purpose: symptom relief for BPH, not prostate size reduction.
• Explain dose and administration: 10 mg once daily after the same meal each day.
• Describe likely onset: days to weeks, with periodic review for benefit and tolerability.
• List common side effects: dizziness, headache, tiredness and occasional GI upset; warn about rare but serious effects such as syncope and severe hypotension.
• Advise on interactions: avoid strong CYP3A4 inhibitors and note additive hypotensive effects with antihypertensives and nitrates.
• Ask about cataract surgery history and advise to inform any eye surgeon of current or past alfuzosin use.

NHS Patient Safety Advice & Follow‑Up

• Recommend baseline blood pressure check and follow‑up BP measurement after initiation or dose changes.
• Review treatment within 4–12 weeks to assess symptom control and side effects, then annually if stable.
• Document counselling in pharmacy records and encourage Yellow Card reporting for suspected adverse reactions.

Patient Handout Template — When To Seek Help

• Seek urgent help for fainting, chest pain, severe shortness of breath or allergic reactions.
• If dizziness or falls occur, stop activities such as driving and contact your GP or pharmacist.
• For missed dose advice: take if plenty of time remains until the next dose; do not double up.

Delivery Across United Kingdom